Chevese Turner, recovering from binge eating disorder and atypical anorexia, hesitated about taking Mounjaro, a diabetes medication with weight loss side effects. Despite her recovery efforts, the medication suppressed her appetite, causing concern. Her endocrinologist did not understand her need for regular meals. GLP-1 medications like Mounjaro and Ozempic are increasingly used for weight loss beyond their intended diabetic purpose, raising alarms. Experts warn these drugs can trigger or worsen eating disorders, complicating recovery for many individuals.
Chevese Turner, after years of recovery from eating disorders, faced concerns when prescribed Mounjaro for diabetes, fearing its weight loss side effect would hinder her progress.
The rise of GLP-1 medications like Ozempic is alarming, as they are increasingly being used for weight loss rather than for their primary purpose of managing diabetes.
Experts emphasize the risk of GLP-1 medications leading to new eating disorders or worsening existing ones, with growing concerns among recovery advocates.
Turner's experience illustrates a disconnect between healthcare professionals and those recovering from eating disorders, highlighting the need for more understanding and support.
Collection
[
|
...
]